Organigram (OGI) Stock Price, News & Analysis

Company Overview

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: C$2.25 to C$2.33
• 50-Day Range: C$2.03 to C$2.60
• 52-Week Range: C$1.67 to C$3.95
• Volume: 85,208 shs
• Average Volume: 296,447 shs
• Market Capitalization: C$244.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$3.43
• Consensus Rating: Moderate Buy

Organigram Stock Analysis - MarketRank™

Organigram scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Organigram has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Organigram has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Organigram is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organigram is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Organigram has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Organigram has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OGI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organigram does not currently pay a dividend.

Dividend Growth

Organigram does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OGI.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.29

News Sentiment

Organigram has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Organigram this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for OGI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Organigram to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Organigram insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$30,275.00 in company stock.

Percentage Held by Insiders

31.32% of the stock of Organigram is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.37% of the stock of Organigram is held by institutions.

OGI Stock Analysis - Frequently Asked Questions

How have OGI shares performed this year?

Organigram's stock was trading at C$1.72 at the start of the year. Since then, OGI shares have increased by 30.8% and is now trading at C$2.25.
View the best growth stocks for 2024 here.

How do I buy shares of Organigram?

Shares of OGI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Organigram own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Innovative Industrial Properties (IIPR), Aurora Cannabis (ACB), Canopy Growth (WEED), Aphria (APHA) and NVIDIA (NVDA).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Cannabis
• Current Symbol: TSE:OGI
• CUSIP: N/A
• CIK: N/A
• Web: www.organigram.ca
• Phone: 844-644-4726
• Fax: N/A
• Employees: 987
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$3.43
• High Stock Price Target: C$4.35
• Low Stock Price Target: C$2.70
• Potential Upside/Downside: +52.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($2.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 13.78
• P/E Growth: 0.42
• Net Income: C$-229,480,000.00
• Net Margins: -153.80%
• Pretax Margin: N/A
• Return on Equity: -54.53%
• Return on Assets: -5.56%

Debt

• Debt-to-Equity Ratio: 1.13
• Current Ratio: 6.95
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: C$149.21 million
• Price / Sales: 1.64
• Cash Flow: C$0.58 per share
• Price / Cash Flow: 3.85
• Book Value: C$2.85 per share
• Price / Book: 0.79

Miscellaneous

• Outstanding Shares: 108,570,000
• Free Float: N/A
• Market Cap: C$244.28 million
• Optionable: Not Optionable
• Beta: 1.13